Cryoablation Provides Long-Term RCC Control

Share this content:
The 5-year disease-free and cancer-specific survival rates were 94.7% and 100%, respectively.
The 5-year disease-free and cancer-specific survival rates were 94.7% and 100%, respectively.

STOCKHOLM—Laparoscopic renal cryoablation of small renal cell carcinoma (RCC) tumors offers optimal and durable cancer control, study findings presented at the European Association of Urology 29th annual congress suggest.

In a single-institution study of 189 patients with a median follow-up of 55 months (range 1-156 months), Alessandro Larcher, MD, of Vita-Salute San Faffaele University in Milano, and colleagues found that the procedure is associated with 5-year disease-free, cancer-specific, and overall survival rates of 94.7%, 100%, and 94.5%, respectively, in patients with RCC.

RELATED: Renal Cell Carcinoma Resource Center

The study population had a median tumor size of 21 mm (range 7-40 mm). The mean ice-ball diameter after surgery was 44.8 mm (range 18-80 mm), and it decreased over time. Histologic examination revealed 118 RCC tumors, 77 benign lesions, and 20 non-diagnostic specimens.

The median time to disease recurrence was 18 months (range 6-48 months).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs